Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 103

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 103
---
 has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes that:

| (1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from                                   
 the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed 
 by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration    
 statement as of the time it was declared effective.                                                                                        |

| (2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment                          
 that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and 
 the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.                            |

| 54 |

<div align='center'>SIGNATURES</div>

Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for filing on
Form F-1 and has duly caused this Post-Effective Amendment No. 2 to the Registration
Statements on Form F-1 to be signed on its behalf by the undersigned, thereunto
duly authorized, in Cardiff, Wales, on this 17th day of November, 2025.

| BIODEXA PHARMACEUTICALS PLC |                                                   |
| By:                         | /s/ Stephen Stamp                                 |
|                             | Stephen Stamp                                     |
|                             | Chief